TC2N: A Potential Drug Target and Biomarker for Membrane Targeting (Tandem) C2 Domain Containing 1

Target Name: TC2N

NCBI ID: G123036

TC2N

TC2N: A Potential Drug Target and Biomarker for Membrane Targeting (Tandem) C2 Domain Containing 1

The C2 domain is a highly conserved region found in various proteins that plays a crucial role in cell signaling, particularly in the regulation of cell adhesion, migration, and invasion. Membrane targeting (Tandem) C2 domain containing 1 (TC2N) is a unique protein that has been identified in various cell types, including human epithelial tissues, and is involved in various cellular processes, including cell adhesion, migration, and signaling pathways.

In recent years, the study of TC2N has gained significant interest due to its potential as a drug target or biomarker. This is mainly attributed to the unique structure of TC2N, which consists of a long N-terminal domain that contains a farnesylated cysteine residue, a transmembrane region, and a C-terminal domain that contains a unique amino acid sequence known as Asp-Glu-Arg-Glu (AGRG) sequence.

TC2N functions as a negative regulator of the RhoA/Rho GTPase signaling pathway, which is involved in cell signaling, including the regulation of cell adhesion, migration, and invasion. The AGRG sequence in the C-terminal domain of TC2N is known to play a crucial role in the regulation of RhoA/Rho GTPase signaling pathway. This sequence is highly conserved in various cell types and is involved in the regulation of various cellular processes, including cell adhesion, migration, and signaling pathways.

In addition to its role in the regulation of the RhoA/Rho GTPase signaling pathway, TC2N has also been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and the regulation of cell cycle progression. The unique structure of TC2N, including the AGRG sequence in its C-terminal domain, has been shown to play a crucial role in its function as a negative regulator of the RhoA/Rho GTPase signaling pathway.

TC2N has also been shown to be a potential drug target due to its unique structure and its involvement in various cellular processes that are associated with the development and progression of various diseases, including cancer. The AGRG sequence in the C-terminal domain of TC2N has been shown to be involved in the regulation of cell adhesion, migration, and the regulation of cell cycle progression, all of which are important factors in the development and progression of various diseases, including cancer.

In conclusion, TC2N is a unique protein that has been identified in various cell types and is involved in various cellular processes, including cell adhesion, migration, and the regulation of cell cycle progression. The AGRG sequence in its C-terminal domain is known to play a crucial role in the regulation of the RhoA/Rho GTPase signaling pathway and has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and the regulation of cell cycle progression. Given its unique structure and its involvement in various cellular processes, TC2N is a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the functions of TC2N and its potential as a drug target or biomarker.

Protein Name: Tandem C2 Domains, Nuclear

The "TC2N Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TC2N comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets